A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2021-08-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-021-00214-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!